Reading LGND? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LGND free→Reading LGND? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LGND free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, while earnings quality is fragile, reported profits aren't backed by cash. Management's recent track record has been steady, and it has a capital-friendly stance. Risk is moderate, and the sector backdrop is a headwind, which may impact growth. Peer multiples imply a price about 116% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified, as it is rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $253.25. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $253 LGND trades at 42× p/e — 2.5× the 17× p/e peer median, and above its own 21× history. The market is re-rating it beyond its own range; our $118 fair value is low-confidence here. Analysts: $239–$289. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 115% near-term growth, well above our forecast of about 9%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 0.80x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.05 → $1.99 (-2.8% / 30d). 3 raised, 1 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$143.
How much price usually moves either way.
On a bad day, this stock has moved -$277.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,407.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Closing this deal will expand Ligand's royalty portfolio and boost growth potential. It is a key step in Ligand's strategy to enhance its market position.
Confirms:The deal will close in Q3 2026. All regulatory approvals are received.
Disproves:The deal does not close. This is due to no shareholder approval or regulatory issues.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LGND yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement. As previously disclosed, on April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Ligand ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among Ligand, XOMA Royalty Corporation, a Nevada corporation (“ XOMA Royalty ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand (“ Merger Sub ”), pursuant to which, and upon the terms and subject to the conditions th…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$239.00 – $289.00 (median $252.00) · 5 analysts · as of 2026-04-30
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LGND Ligand Pharmaceuticals, Inc. | Typical Show detailsSector percentile: 45 of 100 | expensive | moderate |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
4 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Ligand has entered into a strategic partnership with XOMA Royalty through a merger agreement.
Ligand aims to improve its operating income through strategic initiatives and cost management.
Ligand terminated the TR-Beta Program with Viking to focus on more promising opportunities.
Why it matters: Strong growth in royalty revenue will show the good effects of the XOMA deal. It will also show ongoing product sales.
Confirms:Q2 2026 royalty revenue shows growth of at least 50% year-over-year.
Disproves:Q2 2026 royalty revenue growth is below 30% year-over-year.
Why it matters: This termination may change Ligand's future products and finances. It is important to watch its effects.
Confirms:Ligand reports a big drop in R&D costs. It may shift focus away from similar programs.
Disproves:Ligand will keep or increase R&D spending in other good areas, even after the end.
Why it matters: Filspari is a key product for Ligand. Sales growth will indicate market acceptance and revenue potential.
Confirms:Filspari sales exceed $100 million in the first full quarter after FDA approval.
Disproves:Filspari sales fall below $70 million in the first full quarter after FDA approval.
Why it matters: If revenue keeps growing after the merger, it shows the partnership is working.
Confirms:Revenue growth is over 10% year-over-year in the next financial report.
Disproves:Revenue growth is below 5% year-over-year, which may show problems with the merger.
Why it matters: Finalizing this merger could enhance Ligand's growth and revenue potential. It shows progress in strategic partnerships.
Confirms:Look for Ligand or XOMA Royalty to announce the merger is complete.
Disproves:If the merger is delayed or canceled, it may show problems with the partnership.
Why it matters: Progress in the partnership could boost Ligand's growth outlook and investor confidence.
Confirms:A press release confirms milestones or revenue from the partnership.
Disproves:No updates or delays in the partnership's progress over the next quarter.
Why it matters: Knowing how this ending affects Ligand can help understand its future plans.
Confirms:No big negative effects on revenue or operations in the next earnings report.
Disproves:Revenue may drop or problems may arise because the TR-Beta Program is ending.
Results of Operations and Financial Condition. On May 7, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Secur…
Entry into a Material Definitive Agreement. On April 27, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Ligand ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among Ligand, XOMA Royalty Corporation, a Nevada corporation (“ XOMA Royalty ”), and Flex Merger Sub, Inc., a Nevada corporation and wholly-owned subsidiary of Ligand (“ Merger Sub ”), pursuant to which, and upon the terms and subject to the conditions thereof, including, without…
Termination of a Material Definitive Agreement. On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver,…
Other Events. On April 27, 2026, Ligand and Xoma Royalty issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. Also, on April 27, 2026, the investor presentation attached hereto as Exhibit 99.2 was disseminated in connection with the announcement of the Merger Agreement and is incorporated herein by reference. Additional Information and Where to Find It In connection with the…